文献类型：期刊文献

英文题名：Artificial intelligence technologies for enhancing neurofunctionalities: a comprehensive review with applications in Alzheimer's disease research

作者：Gu, Zhirong[1];Ge, Bin[1];Wang, Yuanyuan[2];Gong, Yiping[2];Qi, Mei[1]

第一作者：Gu, Zhirong

通信作者：Gu, ZR[1]

机构：[1]Gansu Prov Peoples Hosp, Dept Pharm, Lanzhou, Gansu, Peoples R China;[2]Gansu Univ Tradit Chinese Med, Sch Pharm, Lanzhou, Gansu, Peoples R China

第一机构：Gansu Prov Peoples Hosp, Dept Pharm, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Peoples Hosp, Dept Pharm, Lanzhou, Gansu, Peoples R China.

年份：2025

卷号：17

外文期刊名：FRONTIERS IN AGING NEUROSCIENCE

收录：;Scopus(收录号：2-s2.0-105014506917);WOS:【SCI-EXPANDED(收录号:WOS:001563210600001)】；

基金：The author(s) declare that financial support was received for the research and/or publication of this article. This research was supported by the Scientific Research Project on Drug Administration of Gansu Provincial Drug Administration (No. 2023GSMPA046) and Natural Science Foundation Project of Gansu Province (No. 24JRRA1061).

语种：英文

外文关键词：Alzheimer's disease; artificial intelligence; machine learning; cognitive training; healthcare innovation

摘要：Alzheimer's disease (AD) is a progressive neurodegenerative condition that impairs memory and cognition, presenting a growing global healthcare burden. Despite major research efforts, no cure exists, and treatments remain focused on symptom relief. This narrative review highlights recent advancements in artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), which enhance early diagnosis, predict disease progression, and support personalized treatment strategies. AI applications are reshaping healthcare by enabling early detection, predicting disease progression, and developing personalized treatment plans. In particular, AI's ability to analyze complex datasets, including genetic and imaging data, has shown promise in identifying early biomarkers of AD. Additionally, AI-driven cognitive training and rehabilitation programs are emerging as effective tools to improve cognitive function and slow down the progression of cognitive impairment. The paper also discusses the potential of AI in drug discovery and clinical trial optimization, offering new avenues for the development of AD treatments. The paper emphasizes the need for ongoing interdisciplinary collaboration and regulatory oversight to harness AI's full potential in transforming AD care and improving patient outcomes.